AR and prostate cancer: Although androgen receptor (AR) pathway is crucial for prostate cancer growth and progression, evidence supporting a favorable risk-benefit ratio of androgen deprivation therapy (ADT) is currently limited to high-risk PCa or metastatic disease [5, 6].